Intranasal Prophylactics For Flu & Coronavirus With Leyden Labs' Koenraad Wiedhaup
![20_12_BPO_BusBiotech_Social_ep56 20_12_BPO_BusBiotech_Social_ep56](https://vertassets.blob.core.windows.net/image/f1d2e506/f1d2e506-15d7-4878-bf52-c97f8baf8442/375_250-20_12_bpo_busbiotech_social_ep56.png)
As Leyden Labs Founder & CEO Koenraad Wiedhaup puts it, we breathe in galaxies of viruses on a daily basis. As those viruses multiply and mutate, our approach to mitigating their risks is largely reactive. That's why his new company is busy developing a prophylactic approach to protecting populations from a host of influenza and coronaviruses via a self-administered intranasal spray. Learn how the company came to be, how its development efforts were buoyed by a recent $40 million series A investment, and why Wiedhaup believes intranasal prophylactics are ready to play a role in prevention of the next pandemic on this episode of the Business of Biotech podcast.
Get unlimited access to:
Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.